[go: up one dir, main page]

AU2001296013A1 - Pgd2 receptor antagonistic pharmaceutical compositions - Google Patents

Pgd2 receptor antagonistic pharmaceutical compositions

Info

Publication number
AU2001296013A1
AU2001296013A1 AU2001296013A AU9601301A AU2001296013A1 AU 2001296013 A1 AU2001296013 A1 AU 2001296013A1 AU 2001296013 A AU2001296013 A AU 2001296013A AU 9601301 A AU9601301 A AU 9601301A AU 2001296013 A1 AU2001296013 A1 AU 2001296013A1
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
receptor antagonistic
pgd2 receptor
antagonistic pharmaceutical
pgd2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296013A
Inventor
Yoshiharu Hiramatsu
Tsunetoshi Honma
Masanao Inagaki
Norihiko Tanimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2001296013A1 publication Critical patent/AU2001296013A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001296013A 2000-11-01 2001-10-26 Pgd2 receptor antagonistic pharmaceutical compositions Abandoned AU2001296013A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-334383 2000-11-01
JP2000334383 2000-11-01
PCT/JP2001/009435 WO2002036583A1 (en) 2000-11-01 2001-10-26 Pgd2 receptor antagonistic pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AU2001296013A1 true AU2001296013A1 (en) 2002-05-15

Family

ID=18810309

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296013A Abandoned AU2001296013A1 (en) 2000-11-01 2001-10-26 Pgd2 receptor antagonistic pharmaceutical compositions

Country Status (5)

Country Link
US (1) US6933317B2 (en)
EP (1) EP1338594A4 (en)
JP (1) JPWO2002036583A1 (en)
AU (1) AU2001296013A1 (en)
WO (1) WO2002036583A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US6980091B2 (en) * 2002-12-10 2005-12-27 Current Technologies, Llc Power line communication system and method of operating the same
US7308103B2 (en) * 2003-05-08 2007-12-11 Current Technologies, Llc Power line communication device and method of using the same
US20060291575A1 (en) * 2003-07-03 2006-12-28 Berkman William H Power Line Communication System and Method
US7321291B2 (en) * 2004-10-26 2008-01-22 Current Technologies, Llc Power line communications system and method of operating the same
CA2533747C (en) * 2003-08-01 2012-11-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
BRPI0508540B8 (en) 2004-03-11 2021-05-25 Actelion Pharmaceuticals Ltd compound, pharmaceutical composition, and use of a compound
US7856032B2 (en) * 2005-04-04 2010-12-21 Current Technologies, Llc Multi-function modem device
US7265664B2 (en) * 2005-04-04 2007-09-04 Current Technologies, Llc Power line communications system and method
US7259657B2 (en) * 2005-06-21 2007-08-21 Current Technologies, Llc Multi-subnet power line communications system and method
US20080012724A1 (en) * 2006-01-30 2008-01-17 Corcoran Kevin F Power line communications module and method
US7852207B2 (en) * 2006-02-14 2010-12-14 Current Technologies, Llc Method for establishing power line communication link
US7859646B2 (en) * 2007-01-24 2010-12-28 Adelphi University Interferometric method for improving the resolution of a lithographic system
US8785682B2 (en) 2007-09-27 2014-07-22 The Trustees Of The University Of Pennsylvania Tetranor PGDM: a biomarker of PGD2 synthesis in vivo
US20110018704A1 (en) * 2009-07-24 2011-01-27 Burrows Zachary M System, Device and Method for Providing Power Line Communications
US20150065343A1 (en) 2012-04-02 2015-03-05 Basf Se Acrylamide compounds for combating invertebrate pests
WO2013167633A1 (en) 2012-05-09 2013-11-14 Basf Se Acrylamide compounds for combating invertebrate pests
KR20160142887A (en) * 2014-04-17 2016-12-13 노파르티스 아게 Polycyclic herg activators
TWI854147B (en) * 2020-08-21 2024-09-01 南韓商治納輔醫藥科技有限公司 Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4037941A1 (en) * 1990-11-23 1992-05-27 Schering Ag CYCLOPENTANETHER DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE
DE4225488A1 (en) 1992-07-30 1994-02-03 Schering Ag New bi:cyclooctane carbacyclin analogues - useful as thromboxane A2 and prostaglandin H2 antagonists
BR9608498B1 (en) * 1995-06-21 2008-11-18 bicyclic amino derivatives and pgd2 antagonist containing them.
JP4120993B2 (en) * 1996-12-12 2008-07-16 塩野義製薬株式会社 Heterocyclic fused benzenecarboxylic amide derivatives and PGD2 antagonists containing the same
CZ297324B6 (en) * 1996-12-13 2006-11-15 Shionogi & Co., Ltd. Benzothiophenecarboxamide derivatives and PGD2 antagonists comprising them
ATE253047T1 (en) * 1997-09-19 2003-11-15 Shionogi & Co COMPOUNDS WITH (2.2.1)BICYCLIC MOLECULAR STRUCTURE
EP1084711B1 (en) * 1998-06-03 2005-05-11 Shionogi & Co., Ltd. Remedies for the treatment of itching containing pgd2 antagonists
EP1295872A4 (en) * 2000-06-02 2007-05-16 Shionogi & Co Drug composition antagonistic to both pgd 2/tx a 22 receptors

Also Published As

Publication number Publication date
WO2002036583A1 (en) 2002-05-10
US20040054003A1 (en) 2004-03-18
US6933317B2 (en) 2005-08-23
EP1338594A1 (en) 2003-08-27
JPWO2002036583A1 (en) 2004-03-11
EP1338594A4 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
AU2001296013A1 (en) Pgd2 receptor antagonistic pharmaceutical compositions
AU781269C (en) Pharmaceutical compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001228665A1 (en) Toll-like receptor
AU2001250205A1 (en) Prostaglandin d2 receptor antagonists
AUPR769501A0 (en) Cytokine receptor 1
AU2002337803A1 (en) Sustained release pharmaceutical compositions
AUPQ441699A0 (en) Pour-on formulations
AUPR602501A0 (en) Sustained release pharmaceutical composition
AU2001273032A1 (en) Cytokine receptor zcytor17
AU2001264657A1 (en) Crf receptor antagonists
AU3556400A (en) Pharmaceutical compositions
AU2001264264A1 (en) Sustained release compositions
AU2002214324A1 (en) Medicinal compositions
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2001260627A1 (en) Drug composition antagonistic to both pgd2/txa2 receptors
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
AU2001248772A1 (en) Sustained release drug compositions
AU2001273919A1 (en) Pharmaceutical compositions
AU6460400A (en) Pharmaceutical compositions
AU2002226048A1 (en) Urotensin-ii receptor antagonists
AU2001263288A1 (en) Crf receptor antagonists
AU6460200A (en) Pharmaceutical compositions
AU4085201A (en) Pharmaceutical composition